Approved BTK Inhibitor Without Covalent Bond for CLL.

Published Date: 08 Dec 2023

In a patient population that had received extensive pretreatment, pirtobrutinib response rates were as high as 72%.

Read Full News

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

Could occupational exposure to sawdust explain this case?

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

— News, features, and commentary about cancer-related issues

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

Todays Updates

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Todays Updates

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Latest News

Could occupational exposure to sawdust explain this case?

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

— News, features, and commentary about cancer-related issues

Case shows importance of accurate preop diagnosis

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Study Warns on Venetoclax in Double-Hit Lymphoma

Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

News, features, and commentary about cancer-related issues

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Death risk cut by 54% with B7-H3-targeting tambotatug pelitecan and risvutatug rezetecan

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Non-significant 4-month PFS increase with sacituzumab govitecan-pembrolizumab, no OS benefit

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

All responding NCCN members reported shortages, priorities identified but solutions still needed

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Omitting prophylactic cranial irradiation led to improved cognitive failure-free survival

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Health news and commentary gathered by MedPage Today staff

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

Bispecific antibody and ADC together impress in early study

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Early efficacy among the highest seen in lung cancer, expert says

Recommended News For You

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?

EMA OKs Two Treatments for Small Cell Lung Cancer

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

Chemotherapy Boosts Survival for Older Patients With TNBC

Recommended Articles For You

Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025 

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Precision Erythropoietic Modeling for Hematologic Disorders 

Digital Cancer Caregiver Coordination Platforms: Advances, Clinical Impact, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Health researchers discuss Medicaid cancer screening trends, best practices

2.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

3.

Approved BTK Inhibitor Without Covalent Bond for CLL.

4.

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

5.

AI-based breast cancer risk technology receives FDA breakthrough device designation

1.

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms

2.

Innovative Solutions in Hematology for Specialists

3.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

4.

Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy 

5.

Evidence-Based Insights in Oncology for Specialists

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

2.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

3.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

5.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot